Jazz Pharmaceuticals to obtain GW Pharma

Jazz Pharmaceuticals and GW Pharma

Jazz Pharmaceuticals is always to obtain medicine that is cannabinoid GW Pharmaceuticals for a whopping sum.

Founded in 1998, GW Pharmaceuticals manufactures CBD-based Epidiolex, which is marketed under the name Epidyolex in the EU and Australia. Epidiolex was the first CBD medicine approved by the USA’s FDA. Epidyolex has been approved in the EU for the treatment of Lennox‑Gastaut syndrome and Dravet syndrome, and in Australia for the treatment of seizures associated with LGS or Dravet.

Epidiolex/ Epidyolex has turned out to be a cash cow for GW Pharma. Preliminary, unaudited product that is net numbers for 2020 released final thirty days suggest Epidiolex raked in approximately USD $510 million for the season in comparison to an estimated $296 million in 2019.

The business announced yesterday this has entered into a agreement that is definitive Jazz Pharmaceuticals that will see Jazz acquire GW Pharma for a total consideration of $7.2 billion. The transaction is expected to finalise in the quarter that is second of 12 months. A thumbs-up from the High Court of Justice of England and Wales and other customary closing conditions.


Founded in 2003, Dublin, Ireland-headquartered Jazz Pharmaceuticals says its medicines are available in more than 90 countries while the Boards of Directors of both companies have signed off on the deal, it’s subject to the approval of GW shareholders. Its focus areas are neuroscience, including sleep and movement disorders, and oncology, including hematologic malignancies and solid tumors. A prescription calcium, magnesium, potassium, and sodium oxybates oral solution used to treat the some of the symptoms associated with narcolepsy.(*)“We are excited to add GW’s industry-leading cannabinoid platform, innovative pipeline and products, which will strengthen and broaden our neuroscience portfolio, further diversify our revenue and drive sustainable, long-term value creation opportunities,” said Bruce Cozadd , chairman and CEO of Jazz Pharmaceuticals.(*)Among the projects in GW’s pipeline is nabiximols (Sativex – a (*) extract containing THC and (*)) for treatment of spasticity associated with MS and spinal cord injury, and preparations containing CBDV (cannabidivarin) and (*) for autism and schizophrenia.(*)Between the two companies is a pro-forma pipeline of 19 clinical development programs across neuroscience and oncology.(* among its medicines is Xywav)

Latest posts